Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Meagan B. Ryan, Oluwadara Coker, Alexey V. Sorokin, et al.
Cell Reports (2022) Vol. 39, Iss. 12, pp. 110993-110993
Open Access | Times Cited: 86

Showing 26-50 of 86 citing articles:

The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Pariyada Tanjak, Amphun Chaiboonchoe, Tharathorn Suwatthanarak, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1098-1098
Open Access | Times Cited: 15
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Ioannis A. Voutsadakis
Critical Reviews in Oncology/Hematology (2023) Vol. 186, pp. 103987-103987
Closed Access | Times Cited: 15
Combined KRASG12Cand SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 14
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry (2025)
Closed Access
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
Miao Hao, Tian‐Xing Zhang, Dan Dong, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
Anirudh Prahallad, Andreas Weiss, Hans Voshol, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4130-4141
Open Access | Times Cited: 12
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment
Cunbo Ma, Di Kang, Pan‐Liang Gao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13534-13549
Closed Access | Times Cited: 4
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade
Panayiotis Anastasiou, Christopher Moore, Sareena Rana, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Bernhard Doleschal, Andreas Petzer, Holger Rumpold
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis
Xiaofeng Liu, Yang Hai, Jinqu Dong, et al.
International Journal of Oncology (2022) Vol. 61, Iss. 6
Open Access | Times Cited: 16
KRAS inhibition in metastatic colorectal cancer: An update
Maliha Nusrat, Rona Yaeger
Current Opinion in Pharmacology (2023) Vol. 68, pp. 102343-102343
Open Access | Times Cited: 10
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg
Joshua C. Rosen, Adrian G. Sacher, Ming‐Sound Tsao
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 9
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer
Motohiro Izumi, Daniel B. Costa, Susumu Kobayashi
Lung Cancer (2024) Vol. 194, pp. 107885-107885
Closed Access | Times Cited: 3
Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
Bennett Adam Caughey, John H. Strickler
Drugs (2023) Vol. 84, Iss. 1, pp. 27-44
Closed Access | Times Cited: 8
Breaking barriers: the latest insights into KRAS G12C inhibitors
Fouad Attieh, Hampig Raphaël Kourié
Future Oncology (2024), pp. 1-4
Closed Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Paolo Ciracì, Vittorio Studiale, Ada Taravella, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2

Scroll to top